Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14705971 | 0.90 | ALDH1A1 (0.61) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL14710304 | 0.90 | MAPT (0.61) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL22614998 | 0.90 | TUBB4A (0.57) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL13312213 | 0.87 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL16797994 | 0.87 | CYP1A2 (0.63) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL11253412 | 0.86 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL17101112 | 0.83 | ALDH1A1 (0.66) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL27465082 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL22768015 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL12294853 | 0.81 | SMN1; SMN2 (0.60) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275744-B2 | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | HAGER BIOSCIENCES, LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240400580-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | HAGER BIOSCIENCES, LLC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20220315602-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | HAGER BIOSCIENCES, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3972587-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | Hager Biosciences, LLC (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020247447-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | HAGER BIOSCIENCES, LLC (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247447-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | HAGER BIOSCIENCES, LLC (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20050020593-A1 | Aryl-heteroaromatic compounds, compositions comprising them and use | AVENTIS PHARMA (FR) | 2005-01-27 | — | — | US | disclosed |
| EP-1237849-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001032604-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2001-05-10 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315602-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CYP1A2 1511/4885CYP2C9 2088/4885CYP2C19 873/4885 |
| US-12275744-B2 | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | HCRTR2, HCRTR1, OXTR | CYP1A2 1476/4885CYP2C9 2137/4885CYP2C19 882/4885 |
| US-20240400580-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CYP1A2 1511/4885CYP2C9 2088/4885CYP2C19 873/4885 |
| US-20050020593-A1 | Aryl-heteroaromatic compounds, compositions comprising them and use | TUBB3, TUBB, TUBB1 | CYP1A2 1664/4885CYP2C9 2724/4885CYP2C19 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.